Thus, the useof bumetanide is limited to subpopulations of patients.159 It remains to be clarified how the hydrophilicbumetanide can be more efficacious than the lipophilic furosemide, how it could be bettertargeted, and whether conditions other than a subset of autism spectrum disorders may betreated with NKCC1 inhibitors. The gene discussed is SLC12A2; the disease is autism spectrum disorder.